Cathepsin B was purified from normal human liver and several human tumour tissues and partially characterized. Three forms of cathepsin B, with molecular masses of 25 kDa, 26 kDa (the two appearing as a doublet) and 30 kDa, were detected in SDS/polyacrylamide gels. The 25-26 kDa doublet was associated with the fractions from tumours and normal liver containing the highest cathepsin B activity. Cathepsin B from both sources showed similar pH optima. Both normal liver and tumour cathepsin B exhibited similar kinetics against selected synthetic substrates. At neutral pH and 24°C, cathepsin B from both normal liver and tumour exhibited a lower Km and a higher kcat /Km than at pH 6.0. Their inhibitory profiles against synthetic inhibitors were also similar. Immunological studies with a monospecific antibody against the mature double-chain form of human liver cathepsin B and an antibody against a cathepsin B-derived synthetic peptide established the immunological similarity of liver and tumour enzymes. The N-terminal sequences of the 25 kDa and 26 kDa forms were identical with that of the heavy chain of the mature double-chain form of human cathepsin B, whereas the N-terminal sequence of the 30 kDa species was identical with that of the single-chain form of human cathepsin B. Treatment of the double-chain form of cathepsin B from normal liver and tumours with the endoglycosidase peptide-N4-(N-acetyl-fl-glucosaminyl)asparagine amidase converted the 26 kDa form into 25 kDa in SDS/polyacrylamide gels, suggesting that cathepsin B may exist as b-oth glycosylated and unglycosylated forms. Our results, in contrast with those reported earlier for mouse cathepsin B, indicate that human liver and tumour cathepsin B are similar.
INTRODUCTION
Intravasation of cancer cells into the circulatory and/or the lymphatic systems and their extravasation out of the vasculature into host parenchymal tissue are necessary prerequisites to successful metastasis. During intravasation and extravasation there is dissolution of the basement membrane by proteinases. The cysteine endopeptidase cathepsin B is one of the proteolytic enzymes that has been implicated in tumour invasion and metastasis (for reviews, see [1] [2] [3] ).
Cathepsin B is a lysosomal enzyme believed to participate in the intracellular degradation and turnover of proteins [4] . Mature cathepsin B exists in two forms, a single-chain form and a double-chain form [5, 6] . Mature single-chain cathepsin B consists of 254 amino acids and is -30 kDa in size [6] . The double-chain form consists of a heavy chain of -25 kDa and a light chain of S kDa [5, 6] . The double-chain form is derived from the singlechain form as a result of enzymic cleavages between residues 47 and 50 with the loss of a dipeptide [6] .
Lysosomal enzymes are directed to the lysosomes via a receptor-mediated system with mannose 6-phosphate as the recognition marker [7, 8] . On the basis of the ability of mannose 6-phosphate to inhibit endocytosis of secreted procathepsin B cathepsin B is thought to be trafficked via mannose phosphate receptors [9] . In I-cell fibroblasts, lysosomal enzymes are secreted as a result of the defective phosphorylation of the mannose 6-phosphate recognition marker [10] [11] [12] . Cathepsin B is secreted from human and murine tumours [13] [14] [15] [16] , but, in contrast with the situation in I-cell disease [11] , not all lysosomal enzymes are secreted [14] . In I-cell fibroblasts, small vesicles containing lysosomal enzymes are observed near the cell periphery [12] .
Cytochemical and immunochemical studies on tumour cells indicate a similar peripheral distribution of cathepsin B activity and protein [17] [18] [19] . This presence of cathepsin B in small vesicles near the periphery of tumour cells may be responsible for the co-sedimentation of cathepsin B with plasma membrane/ endosomal fractions of tumour cells, a phenomenon we have observed in all malignant cells of murine and human origin (for reviews, see [1] [2] [3] 20] ).
This altered distribution of cathepsin B in tumours may indicate changes at one or more steps in the normal pathway for biosynthesis and delivery of cathepsin B to lysosomes (i.e., alterations in transcription/translation, co-and post-translational processing and/or in intracellular trafficking). In the present study we purified and characterized cathepsin B from human tumours in order to evaluate possible changes in cathepsin B itself.
MATERIALS AND METHODS Materials
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64), dithiothreitol (DTT), leupeptin, aprotinin and pepstatin A were purchased from Sigma (St. Louis, MO, U.S.A.). benzyloxycarbonyl-Phe-Arg p-nitroanilide (Z-Phe-Arg-pNA) and Z-ArgArg-pNA were from Bachem U.S. (Philadelphia, PA, U.S.A.). benzyloxycarbonyl-Arg-Arg N-methylcoumarylamide (Z-ArgArg-NHMec), Z-Phe-Arg-NHMec, Sephadex-aminohexyl-GlyPhe-Gly semicarbazone (Sephadex-Ahx-Gly-Phe-Gly-SC), and Z-Phe-Ala-CHN2 were obtained from Enzyme System Products (Livermore, CA, U.S.A.). Nitrocellulose membranes were purchased from Bio-Rad (Richmond, CA, U.S.A.). Immobilon-P Abbreviations used: Con A, concanavalin A; E-64, L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane; Endo F, endo-fl-N-acetylglucosaminidase F; PNGase F, peptide-N2-(N-acetyl-,f-glucosaminyl)asparagine amidase; Z, benzyloxycarbonyl; NHMec, N-methylcoumartin; -CHN2, -diazomethane; DTT, dithiothreitol; -pNA, p-nitroanilide; Ahx, aminohexyl; -SC, semicarbazone; Aan, a-aminoacetonitrile.
t To whom all correspondence should be addressed. The affinity resin Sephadex-Ahx-Gly-Phe-Gly-SC (5 ml) was washed twice with 0.1 M-Tris, pH 8.0, and equilibrated first with 50 mM-sodium formate/ 1 mM-EDTA, pH 4.0, and then with buffer A. DTT was added to the concentrated sample at a final concentration of 2 mm. The sample was mixed with the affinity resin at room temperature for 2 h. The resulting slurry was placed in a column (1.0 cm x 7.0 cm) and the unbound fractions collected. The column was subsequently washed with 50 ml of buffer A containing 0.5 M-NaCl at a flow rate of1 ml/min, followed by 50 mM-sodium formate, pH 4. Cathepsin B was eluted with 50 mM-sodium formate, pH 4.0, containing 1.5 mm-2,2-dipyridyl disulphide and concentrated to a volume of 3-5 ml as described above.
The the transfer buffer. When transfer was complete (30 V overnight and 70 V for 1 h), membranes were developed utilizing the purified antibodies described above and horseradish peroxidase according to the Bio-Rad procedure. Alternatively, the membranes were developed with the more sensitive ECL Western-blot detection system (Amersham, Arlington Heights, IL, U.S.A.). Dry milk (5 %) and Tween were used as blocking agents for both methodologies.
Peptide sequencing. For N-terminal sequencing, samples containing purified cathepsin B were subjected to SDS/PAGE (see above), except that the running buffer contained 0.1 mM-sodium thioglycollate in the upper chamber and the SDS was recrystallized as described by Hunkapiller et al. [25] . The gel was transferred to Immobilon-P membrane and the membrane stained with Coomassie Brilliant Blue according to the manufacturer's (Millipore) instructions. Direct protein microsequencing from the Immobilon-P was performed by Dr. Joseph Leykam of the Macromolecular Structure Facility of Michigan State University (East Lansing, MI, U.S.A.).
Carbohydrate detection. To detect the presence of carbohydrate moieties, the purified double-chain forms of cathepsin B from both normal human liver and human tumour tissues were incubated with Endo F and/or PNGase F as described previously [26, 271 . The samples were then subjetedtoSDS/PAGE and the gels silver-stained for analysis. In addition, double-chain cathepsin B from tumour was applied to a 3 ml concanavalin A 1992 (Con A)-Sepharose column equilibrated with 0.02 M-Tris/HCI/ 0.5 M-NaCl, pH 7.4, and the unbound fractions collected. Bound cathepsin B was eluted in 20-30 ml of the equilibration buffer containing 0.5 M-a-D-mannose. Unbound fractions and eluted fractions were then concentrated to 300 ,l and the buffer exchanged to 50 mM-sodium acetate/1 mM-EDTA, pH 5.2, utilizing a Centricon-10 microconcentrator (Amicon, Beverly, MA, U.S.A.). Portions of each sample were analysed by immunoblot analysis as described above.
Cathepsin B assays. Stopped assays. The enzyme was activated with 5 mM-DTT and 2.5 mM-EDTA at pH 5.2 for 15 min at 37 'C. The assay was performed by the addition of citrate phosphate buffer (final concn. 0.1 M), pH 6.2, and Z-Arg-ArgNHMec as substrate (final concn. 5 ,M). The Inhibitor studies. The enzymes were assayed in the presence of various inhibitors as described above under 'Stopped assays'.
The inhibitor was added to the mixture after the addition of the assay buffer and incubated for 5 min before the addition of the substrate. The percentage inhibition was determined by comparing the activities with those measured for positive controls without inhibitors. The apparent K, was calculated utilizing the fractional-inhibition formula for competitive inhibition at a single concentration of the inhibitor as described by Nicklin & Barrett [28] .
Protein determination. The Micro BCA Kit (Pierce, Rockford, IL, U.S.A.) was utilized to determine protein concentrations; the procedure described by the manufacturer was followed.
RESULTS

Purification of cathepsin B
Cathepsin B was purified from normal human liver and human tumour tissues by acid fractionation, acetone fractionation, affinity chromatography and cation-exchange chromatography. Table 1 shows a purification ofcathepsin B from human sarcoma. Rich et al. [22] had reported a purification factor of 361 for human liver cathepsin B as compared with our 673-fold purification after the affinity column. Our calculations are based on the homogenate as the starting point, whereas those of Rich et al. [22] were based on the post-autolysis (acid-fractionation) step. When our fold purification was calculated from the acidfractionation step, it was 224-fold or somewhat less than that reported by Rich et al. [22] . This lesser fold purification may be due to overloading of the affinity column, as our yield was considerably less than that reported by Rich et al. [22] . In (Fig. 4) to the N-terminal sequence of the single-chain form of human cathepsin B [6] . The 25 and the 26 kDa bands of the doublet had identical N-terminal sequences, both of which corresponded to the N-terminus of the heavy chain of the double-chain form of cathepsin B (Fig. 4) analysed by immunoblotting. The unbound fractions contained both the 25 kDa and the 26 kDa bands (Fig. 6 ). This is not surprising, since the carbohydrate structures determined for pig and rat cathepsin B [29, 30] suggest that binding to Con A will be with low affinity. However, as shown in Fig. 6 , a small amount of cathepsin B did bind to Con A-Sepharose and was eluted with a-D-mannose. The mobility of the eluted cathepsin B in SDS/ polyacrylamide gels corresponded to 26 kDa (Fig. 6) . Since only the double-chain form with the 26 kDa heavy chain was eluted from the Con A-Sepharose column, we concluded that the 25 kDa heavy chain of cathepsin B lacks an oligosaccharide chain with sufficient terminal mannose residues to bind to Con A. pH studies Cathepsin B from normal liver and tumours was assayed at various pH values to determine its pH optimum. Cathepsin B from both liver and tumour tissues appeared to have optimal activity from pH 5.5 to 7.5 (results not shown).
Determination of kinetic constants
Kinetic constants for the hydrolysis of synthetic substrates by cathepsin B from normal human liver and human sarcoma and synthetic substrates are summarized in Table 2 . We tested cathepsin B from human sarcoma because this tumour could be obtained in amounts sufficient for the purification of the quantities of cathepsin B required for kinetic analysis. A comparison of the kinetic constants for the hydrolysis of Z-Phe-Arg-pNA at pH 6.0 and for Z-Arg-Arg-pNA at pH 6.0 and 7.4 (Table 2) indicated that the human sarcoma enzyme was catalytically identical with normal human liver cathepsin B under the conditions of the present studies. The kcat/Km of both liver and (Table 3) .
DISCUSSION
The association of cathepsin B activity with plasma membrane/endosomal fractions is the most striking difference between tumours and normal tissues (for reviews, see [1] [2] [3] 20] ). The nature of this association has not been determined. However, the present study suggests that cathepsin B in malignant tumours does not have major structural modifications. Human cathepsin B from normal liver and tumours were similar in respect of their molecular masses. N-terminal sequences, antibody reactivities, Mature human cathepsin B has been reported to exist in two forms: a single-chain form of -30 kDa and a double-chain form with a heavy chain of -25 kDa and a light chain of -, 5 kDa [4] . We detected both single-and double-chain forms in fractions from both normal human liver and human tumours that contain cathepsin B activity (Fig. 1 ). In addition, we detected two isoforms of the heavy chain of the double-chain form of cathepsin B (Fig. 1) . We confirmed that all three forms were cathepsin B by reactivity with monospecific antibodies (Figs. 2 and 3 ) and by Nterminal sequencing (Fig. 4) . Cathepsin B purified from normal human kidney also exists as three forms of similar molecular mass [35] .
In the present study the major peak of cathepsin B activity was associated with fractions containing only the double-chain form of the enzyme (Fig. 1 ). This contrasts with the report by Hanewinkel etal. [9] that the single-chain form of human fibroblast cathepsin B is more active than the double-chain form. However, purified proteins were not assayed in the latter study. In a recent study in which a comprehensive kinetic analysis was carried out with the single-chain form of recombinant rat cathepsin B, the kinetic constants are similar to those reported here for double-chain forms of human cathepsin B [36] .
Takahashi et al. [37] have contended that cathepsin B is an exopeptidase without endopeptidase activity, on the basis of its inability to cleave certain peptide and protein substrates (with the exception of those for dipeptidyl dipeptidases and aminopeptidases). A recent report by Mason [38] on the reaction of cathepsin B with a2-macroglobulin and results from our laboratory on the degradation of laminin, collagen type IV and fibronectin by cathepsin B [39, 40] have re-established that cathepsin B has endopeptidase activity.
Cathepsin B has been reported to have low affinity towards Con A [4, 30] , a finding consistent with the reports that cathepsin B has abbreviated forms of the high-mannose type oligosaccharides normally found on lysosomal enzymes [29, 30, 41] . The trimming of the high-mannose oligosaccharide chains on cathepsin B may occur during proteolytic processing to the mature form, since Nishimura et at. [42] have separated rat liver procathepsin B from mature cathepsin B by exploiting the ability of procathepsin B to bind to Con A. However, we have demonstrated that the difference between the 25 kDa and 26 kDa heavy chains of human liver and tumour cathepsin B was an -1 kDa N-linked high-mannose-type oligosaccharide moiety.
Khalfan [43] contends that active cathepsin B has no affinity for Con A, although the data he presents indicate that , % of cathepsin B binds to Con A-Sepharose. A fraction of the purified mature double-chain cathepsin B from human sarcoma, corresponding to the 26 kDa band on SDS/PAGE and to the fractions with highest activity, bound to a Con A-Sepharose column (Fig. 6) . Thus a portion of the mature cathepsin B has the high-mannose carbohydrates necessary for binding to Con A.
Cathepsin B, normally present in the lysosomes, is believed to have optimal activity under the acidic conditions found in the lysosomal lumen [4] . Cathepsin B from normal liver has been reported to have optimal activity at about pH 5.5-6.5, but to be inactive and unstable at pH values at or above 7.0 [4, 21, [44] [45] [46] . In the present study, cathepsin B from both normal liver and tumour tissues had considerable activity at about neutral pH. The kinetic data (Table 2 ) indicated that cathepsin B from both liver and tumour tissues had greater activity when assayed at neutral pH than acidic pH (consistent with results obtained from recombinant rat cathepsin B [36] ). Nevertheless, the kinetic data were obtained at 24°C against synthetic substrates, conditions not encountered in vivo. Previous work by Willenbrock & Brocklehurst [46] and Maciewicz et al. [47] have shown that activity and stability of cathepsin B at higher pH are temperatureand substrate-dependent. Willenbrock & Brocklehurst [46] demonstrated that cathepsin B is unstable at 37°C when tested against synthetic substrates. Maciewicz et al. [47] , on the other hand, found that cathepsin B is active at neutral pH at 37°C when tested against the protein substrates collagens types II and XI. We have also shown cathepsin B from both normal and tumour tissues to be active against the protein substrates laminin and fibronectin at neutral pH at 37°C [40] . Under physiological conditions of pH and temperature, cathepsin B also autodegrades at a higher rate than at acidic pH, resulting in a loss of activity [40] . This autodegradation and therefore the loss of activity are slowed in the presence of alternative protein substrates [40] . Thus, although pH and temperature may cause conformational changes in cathepsin B in vitro which can render the enzyme unstable, the larger protein substrates present in vivo may stabilize the enzyme so that it retains activity at neutral pH.
